oppn parties Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

News Snippets

  • Supreme Court dismisses industry bodies' plea to stop the SBI from disclosing the numbers of the electoral bonds
  • NDA finalizes seat sharing in Bihar - BJP 17, JD(U) 16 aqnd LJP 5
  • Election Commission removes Home secretaries of Gujarat, UP, Bihar, HP, Uttarakhand and Jharkhand and the DGP of Bengal
  • Telangana governor Tamilsai Soundararajan resigned from his post and is likely to contest for the BJP from Chennai
  • ED claims K Kavitha of the BRS paid Kejriwal and Sisodia Rs 100cr in the alleged liquor scam in Delhi. AAP says this is a ploy to malign their names
  • Supreme Court tells SBI not to be selective and disclose full details of electoral bonds
  • With the US Department of Justice rpobing bribery charges against Adani group companies, Adani group shares and bonds are under pressure
  • Narayan Murthy gifts Infosys shares worth Rs 240cr to his 4-month-old grandson
  • Tata Sons to sell Rs 9362cr worth shares of TCS to pare debt
  • Stocks were positive on Monday - Sesex climbed 104 points to 72748 and Nifty 32 points to 22055
  • IOA dissolves the ad-hoc panel and gives full control of WFI to elected panel headed by Brij Bhushan aide Sanjay Singh
  • Controversy erupts after BJP leader Tathagata Roy prescribes the cicumcision test for those seeking citizenship under CAA. TMC calls it a 'vulgar jibe'
  • Rahul Gandhi concludes his Bharat Jodo Nyay Yatra in Mumbai, holds a mega rally at Shivaji Park and says the BJP does not have the courage to change the Constitution despite making a lot of noise in that regard
  • ED issues two fresh summons to Delhi CM Arvind Kejriwal in the liqour excise case just a day after he got bail in the earlier cases of ignoring the summons
  • A 14-year-old girl killed herself after she was strip-searched at school in Bagalkot in Karnataka
Election Commission orders removal of home secretaries of 6 states and the DGP of Bengal
oppn parties
Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

By Sunil Garodia
First publised on 2022-12-16 06:50:54

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

A few months ago, the World Health Organization (WHO) had insinuated that India's Maiden Pharmaceuticals, the Haryana-based drug manufacturer, had supplied sub-standard paediatric cough syrups to Gambia and linked it to the death of 66 children in that country. Now, after the results of the tests conducted on the samples of final products and raw materials drawn from the manufacturing facilities of the drug firm have confirmed that there was nothing wrong with the syrups and they met with all prescribed standards, the government of India has slammed the WHO for drawing hasty conclusions and unfairly linking the death of the children to the alleged infirmities in the cough syrups without conducting a thorough test. Surprisingly, as the government has stated, WHO has, till now, refused to share any details as to how it arrived at the conclusion that linked the deaths to the cough syrups despite several reminders.

The hasty action of WHO is not acceptable, more so as it has failed to produce material to support the claims. India has earned the reputation of supplying excellent quality pharmaceuticals products all over the world. Its companies follow good manufacturing practices and are being regularly inspected by local authorities and even international authorities. If baseless charges, not backed by supporting material, are made against one Indian company it will damage the reputation of the entire industry.

India must take up the matter with WHO at the highest level. It should submit the findings of the tests conducted and demand the same from WHO. If WHO is unable to substantiate its claims then it should issue an unconditional apology and clear the drug manufacturer. Further, there must a defined process at WHO through which such alerts are issued. It must do so only after conducting acceptable preliminary tests and provide the results to the government of the originating country. In case of Maiden Pharmaceuticals it seems that WHO is trying to hide its inefficiency as it has failed to provide supporting material even though nearly three months have passed since it first sounded the alert. This is damaging for the whole pharmaceuticals ecosystem.